Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow‐up until age 3 years
- 18 October 2011
- journal article
- research article
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 42 (1), 112-122
- https://doi.org/10.1111/j.1365-2222.2011.03885.x
Abstract
Background Allergic disease has been associated with altered intestinal microbiota. Therefore, probiotics have been suggested as a potential treatment for eczema. Objective We investigated whether dietary supplementation of infants with eczema at age 3–6 months with Lactobacillus paracasei CNCM I‐2116 or Bifidobacterium lactis CNCM I‐3446 had a treatment effect or altered allergic disease progression. Methods Primary outcome included eczema severity (SCORing Atopic Dermatitis, SCORAD) 3 months post‐randomization. Secondary: SCORAD (other visits); infant dermatitis quality of life (IDQoL); gastrointestinal permeability; urinary eosinophilic protein X; allergen‐sensitization; allergic symptoms (age 12, 18, 36 months). A total of 208 infants aged 3–6 months with physician‐diagnosed eczema were recruited; 137/208 (SCORAD≥10, consuming ≥200 mL standard formula/day) were randomized to daily supplements containing L. paracasei or B. lactis or placebo for a 3‐month period, while receiving extensively hydrolysed whey‐formula (dairy‐free diet). There were two open observational groups, one group exclusively breastfed (n = 22) and the other, standard formula‐fed (n = 49). Trial number: ISRCTN41490500. Results Eczema severity decreased significantly over time in all groups. No significant difference was observed between randomized groups after 12‐week treatment‐period (SCORAD‐score pre‐/post‐intervention: B. lactis 25.9 [95% CI: 22.8–29.2] to 12.8 [9.4–16.6]; L. paracasei 25.4 [22.1–29] to 12.5 [9.2–16.4]; placebo 26.9 [23.4–30.6] to 11.8 [9.6–14.3]; P = 0.7). Results were similar when analysis was controlled for allergen‐sensitization, or when only sensitized infants were analysed. No differences were found for secondary outcomes. No difference was observed in SCORAD‐score between randomized and observational groups. Conclusion and Clinical Relevance We found no benefit from supplementation with B. lactis or L. paracasei in the treatment of eczema, when given as an adjunct to basic topical treatment, and no effect on the progression of allergic disease from age 1 to 3 years.Keywords
This publication has 35 references indexed in Scilit:
- Effect of Lactobacillus paracasei ST11 on a nasal provocation test with grass pollen in allergic rhinitisClinical and Experimental Allergy, 2011
- Probiotics for treating eczemaEmergencias, 2008
- Bifidobacterium pseudocatenulatum is associated with atopic eczema: A nested case-control study investigating the fecal microbiota of infantsJournal of Allergy and Clinical Immunology, 2008
- Randomized, placebo‐controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancyAllergy, 2007
- Prospective, randomized controlled trial onLactobacillus rhamnosusin infants with moderate to severe atopic dermatitisBritish Journal of Dermatology, 2006
- No effects of probiotics on atopic dermatitis in infancy: a randomized placebo‐controlled trialClinical and Experimental Allergy, 2006
- Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitisThe Journal of Pediatrics, 2004
- Induction by a Lactic Acid Bacterium of a Population of CD4+T Cells with Low Proliferative Capacity That Produce Transforming Growth Factor β and Interleukin-10Clinical and Diagnostic Laboratory Immunology, 2001
- Adherence of Probiotic Bacteria to Human Intestinal Mucus in Healthy Infants and during Rotavirus InfectionClinical and Diagnostic Laboratory Immunology, 2001
- Clinical Validation and Guidelines for the SCORAD Index: Consensus Report of the European Task Force on Atopic DermatitisDermatology, 1997